These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 21607020)

  • 21. Deep Brain Stimulation and Medication Management in Parkinson's Disease.
    Hutchinson K; Wick JY
    Consult Pharm; 2016 Feb; 31(2):73-84. PubMed ID: 26842685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deep brain stimulation for advanced Parkinson's disease.
    Rodriguez-Oroz MC
    Lancet Neurol; 2010 Jun; 9(6):558-9. PubMed ID: 20434404
    [No Abstract]   [Full Text] [Related]  

  • 23. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
    Clarke CE; Worth P; Grosset D; Stewart D
    Parkinsonism Relat Disord; 2009 Dec; 15(10):728-41. PubMed ID: 19805000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
    Aschermann Z; Kovács N; Komoly S
    Ideggyogy Sz; 2013 May; 66(5-6):209-10. PubMed ID: 23909024
    [No Abstract]   [Full Text] [Related]  

  • 25. Use of advanced therapies for Parkinson's disease in Norway.
    Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
    Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of deep brain stimulation and levodopa on postural sway in Parkinson's disease.
    Rocchi L; Chiari L; Horak FB
    J Neurol Neurosurg Psychiatry; 2002 Sep; 73(3):267-74. PubMed ID: 12185157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Comprehensive Approach to Parkinson's Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects.
    Muleiro Alvarez M; Cano-Herrera G; Osorio Martínez MF; Vega Gonzales-Portillo J; Monroy GR; Murguiondo Pérez R; Torres-Ríos JA; van Tienhoven XA; Garibaldi Bernot EM; Esparza Salazar F; Ibarra A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease.
    Arai E; Arai M; Uchiyama T; Higuchi Y; Aoyagi K; Yamanaka Y; Yamamoto T; Nagano O; Shiina A; Maruoka D; Matsumura T; Nakagawa T; Katsuno T; Imazeki F; Saeki N; Kuwabara S; Yokosuka O
    Brain; 2012 May; 135(Pt 5):1478-85. PubMed ID: 22522940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CVT-301 for the treatment of Parkinson's disease.
    Shpiner DS; Bette S; Di Luca DG; Margolesky J
    Expert Rev Neurother; 2019 Jul; 19(7):603-611. PubMed ID: 31104518
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of Parkinson's disease a review of current and new therapies.
    Mendis T; Suchowersky O; Lang A; Gauthier S
    Can J Neurol Sci; 1999 May; 26(2):89-103. PubMed ID: 10352867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and emerging treatments in Parkinson's disease.
    Tan AK
    Ann Acad Med Singap; 2001 Mar; 30(2):128-33. PubMed ID: 11379409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deep brain stimulation state of the art and novel stimulation targets.
    Ponce FA; Lozano AM
    Prog Brain Res; 2010; 184():311-24. PubMed ID: 20887882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment possibilities in advanced Parkinson's disease].
    Takáts A; Nagy H; Radics P; Tóth A; Tamás G
    Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current strategies in the treatment of Parkinson's disease and a personalized approach to management.
    Diaz NL; Waters CH
    Expert Rev Neurother; 2009 Dec; 9(12):1781-9. PubMed ID: 19951137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
    Richter D; Bartig D; Jost W; Jörges C; Stumpe B; Gold R; Krogias C; Tönges L
    J Neural Transm (Vienna); 2019 Jul; 126(7):879-888. PubMed ID: 31222604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parkinson's Disease.
    Reich SG; Savitt JM
    Med Clin North Am; 2019 Mar; 103(2):337-350. PubMed ID: 30704685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eight-year follow-up outcome of subthalamic deep brain stimulation for Parkinson's disease: Maintenance of therapeutic efficacy with a relatively low levodopa dosage and stimulation intensity.
    Jiang L; Chen W; Guo Q; Yang C; Gu J; Xian W; Liu Y; Zheng Y; Ye J; Xu S; Hu Y; Wu L; Chen J; Qian H; Fu X; Liu J; Chen L
    CNS Neurosci Ther; 2021 Nov; 27(11):1366-1373. PubMed ID: 34350691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.
    Lhommée E; Wojtecki L; Czernecki V; Witt K; Maier F; Tonder L; Timmermann L; Hälbig TD; Pineau F; Durif F; Witjas T; Pinsker M; Mehdorn M; Sixel-Döring F; Kupsch A; Krüger R; Elben S; Chabardès S; Thobois S; Brefel-Courbon C; Ory-Magne F; Regis JM; Maltête D; Sauvaget A; Rau J; Schnitzler A; Schüpbach M; Schade-Brittinger C; Deuschl G; Houeto JL; Krack P;
    Lancet Neurol; 2018 Mar; 17(3):223-231. PubMed ID: 29452685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.